Is entecavir (ETV) effective for the treatment of HBeAg-positive hepatitis B (HBV) (Hep B)?

Updated: Jun 08, 2021
  • Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF; Chief Editor: BS Anand, MD  more...
  • Print

With regard to the HBeAg-positive population, administration of 0.5 mg of entecavir in patients who were naïve to nucleoside analogues relative to patients who received 100 mg of 3TC for a duration of 48 weeks resulted in histologic improvement in 72% of the entecavir group compared with 62% of the 3TC group. [77] Undetectable serum HBV DNA levels were reported in 67% of entecavir-treated patients, compared with 36% of 3TC-treated patients.

In addition, normalized ALT levels were achieved in 68% of the entecavir group, versus 60% of the 3TC group. [77] The mean reduction in serum HBV DNA from baseline to week 48 was 6.9 log copies/mL (on a base-10 scale) in the entecavir-treated patients, relative to 5.4 log copies/mL in the 3TC-treated patients. HBeAg seroconversion occurred in 21% of patients treated with entecavir and in 18% of patients treated with 3TC. [77]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!